<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Receptor-like protein tyrosine phosphatase kappa (PTPRK) has been shown to exhibit homophilic binding </plain></SENT>
<SENT sid="1" pm="."><plain>It is a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor in primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study investigated the expression of PTPRK in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and the biological impact of PTPRK on <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Expression of PTPRK protein and gene transcript was examined in a cohort of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>The association of PTPRK transcript level and pathological and clinical aspects was then analysed </plain></SENT>
<SENT sid="5" pm="."><plain>Knockdown of PTPRK in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells was performed using a specific anti-PTPRK transgene </plain></SENT>
<SENT sid="6" pm="."><plain>The impact of PTPRK knockdown on <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells was investigated using in vitro cell function assays </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Lower levels of PTPRK transcripts were seen in the advanced <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The reduced PTPRK transcript levels were associated with poor prognosis of the disease </plain></SENT>
<SENT sid="9" pm="."><plain>PTPRK transcript levels were decreased in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> of patients who died from <z:hpo ids='HP_0003002'>breast cancer</z:hpo> or had <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with lower expression of PTPRK had shorter survival compared with those higher expression levels of PTPRK </plain></SENT>
<SENT sid="11" pm="."><plain>Knockdown of PTPRK resulted in increased proliferation, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, invasion, and migration of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells in vitro </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Decreased expression of PTPRK in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> is correlated with poor prognosis </plain></SENT>
<SENT sid="13" pm="."><plain>PTPRK is a negative regulator of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, invasion, migration, and proliferation of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cells </plain></SENT>
<SENT sid="14" pm="."><plain>This suggests that PTPRK is a potential <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>